Condition
Neurofibromatosis Type 1 (NF1)
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Completed1
Active Not Recruiting1
Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03962543Phase 2Active Not Recruiting
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
NCT07327164Completed
Precision Medicine for Neurocutaneous Syndromes in Western China
NCT06961565Phase 1Recruiting
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
NCT01968590Phase 2TerminatedPrimary
Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)
Showing all 4 trials